DE60303238D1 - Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten - Google Patents

Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten

Info

Publication number
DE60303238D1
DE60303238D1 DE60303238T DE60303238T DE60303238D1 DE 60303238 D1 DE60303238 D1 DE 60303238D1 DE 60303238 T DE60303238 T DE 60303238T DE 60303238 T DE60303238 T DE 60303238T DE 60303238 D1 DE60303238 D1 DE 60303238D1
Authority
DE
Germany
Prior art keywords
crth2
pyrimidine
treatment
acetic acid
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60303238T
Other languages
English (en)
Other versions
DE60303238T2 (de
Inventor
Tai Wie
Yuji Koriyama
Takashi Yoshino
Hiroki Sato
Kazuho Tanaka
Hiromi Sugimoto
Yoshihisa Manabe
Kevin Bacon
Klaus Urbahns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB007 Inc
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of DE60303238D1 publication Critical patent/DE60303238D1/de
Application granted granted Critical
Publication of DE60303238T2 publication Critical patent/DE60303238T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
DE60303238T 2003-04-25 2003-04-25 Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten Expired - Lifetime DE60303238T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (de) 2003-04-25 2003-04-25 Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten

Publications (2)

Publication Number Publication Date
DE60303238D1 true DE60303238D1 (de) 2006-04-06
DE60303238T2 DE60303238T2 (de) 2006-09-14

Family

ID=32946880

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60303238T Expired - Lifetime DE60303238T2 (de) 2003-04-25 2003-04-25 Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602004030907T Expired - Lifetime DE602004030907D1 (de) 2003-04-25 2004-04-14 Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004030907T Expired - Lifetime DE602004030907D1 (de) 2003-04-25 2004-04-14 Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate

Country Status (33)

Country Link
US (2) US7812160B2 (de)
EP (2) EP1471057B1 (de)
JP (2) JP4671955B2 (de)
KR (1) KR101110491B1 (de)
CN (2) CN1809539B (de)
AR (1) AR043885A1 (de)
AT (2) ATE316077T1 (de)
AU (1) AU2004233966B2 (de)
BR (1) BRPI0409733A (de)
CA (1) CA2523439C (de)
CL (1) CL43596B (de)
CY (1) CY1111295T1 (de)
DE (2) DE60303238T2 (de)
DK (2) DK1471057T3 (de)
DO (1) DOP2004000875A (de)
ES (2) ES2257616T3 (de)
GT (1) GT200400079A (de)
HK (1) HK1095320A1 (de)
HN (1) HN2004000129A (de)
IL (1) IL171566A (de)
MX (1) MXPA05011399A (de)
MY (1) MY147984A (de)
NO (1) NO20055588L (de)
NZ (1) NZ543693A (de)
PE (1) PE20050143A1 (de)
PL (1) PL1633726T3 (de)
PT (2) PT1471057E (de)
RU (1) RU2361865C2 (de)
SI (1) SI1633726T1 (de)
TW (1) TWI353980B (de)
UY (1) UY28286A1 (de)
WO (1) WO2004096777A1 (de)
ZA (1) ZA200508722B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
SG10201900535UA (en) * 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
SI1718649T1 (sl) * 2004-01-31 2009-10-31 Actimis Pharmaceuticals Inc Derivati imidazo 1,2-c pirimidinilocetne kisline
CN1930162B (zh) 2004-03-11 2010-06-16 埃科特莱茵药品有限公司 四氢吡啶并吲哚衍生物
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
UY29223A1 (es) 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
RU2453540C2 (ru) 2005-04-21 2012-06-20 Лаборатуар Сероно С.А. 2,3-замещенные пиразинсульфонамиды в качестве ингибиторов crth2
UA90145C2 (ru) 2005-05-24 2010-04-12 Лаборатуар Сероно С.А. Трициклические спиро-производные как модуляторы crth2
PE20070589A1 (es) 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
BRPI0712301A2 (pt) * 2006-06-09 2012-01-17 Icos Corp composto, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用
WO2008156781A1 (en) * 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Amine salts of a crth2 antagonist
UA99138C2 (ru) * 2007-06-21 2012-07-25 Актимис Фармасьютикалз, Инк. Частичка антагониста crth2 (варианты)
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
AR068633A1 (es) 2007-09-25 2009-11-25 Actimis Pharmaceuticals Inc Pirimidinas sustituidas con 2-s- bencilo como antagonistas de crth2
DK2205569T3 (da) * 2007-09-25 2012-05-21 Actimis Pharmaceuticals Inc Alkylthiopyrimidiner som crth2-antagonister
BRPI0907364A2 (pt) 2008-02-01 2015-07-14 Amira Pharmaceuticals Inc Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
CN102076661B (zh) 2008-07-03 2014-04-09 潘米拉制药公司 ***素d2受体的拮抗剂
CA2735722A1 (en) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
EP2377851A4 (de) * 2008-12-25 2012-06-20 Taisho Pharmaceutical Co Ltd Isochinolinderivat
US20120129820A1 (en) 2009-02-09 2012-05-24 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
EP2461809A4 (de) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Pharmazeutische zusammensetzungen für die augen aus dp2-rezeptor-antagonisten
SG10201404662YA (en) 2009-08-05 2014-10-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
EP2504319A1 (de) * 2009-11-24 2012-10-03 Boehringer Ingelheim International GmbH Verfahren zur herstellung eines polymorphs des cholinsalzes eines pyrimidin-5-yl-essigsäurederivats
KR20120115989A (ko) 2010-01-06 2012-10-19 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
PL2528901T3 (pl) 2010-01-27 2015-11-30 Boehringer Ingelheim Int Związki pirazolowe jako antagoniści CRTH2
TW201212916A (en) 2010-06-23 2012-04-01 Taisho Pharmaceutical Co Ltd Isoquinoline derivative
JP5800898B2 (ja) 2010-07-05 2015-10-28 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
EP2598145A1 (de) * 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmazeutische zusammensetzungen zur behandlung von atemwegs- und entzündungserkrankungen
EP2598143A1 (de) 2010-07-28 2013-06-05 Boehringer Ingelheim International GmbH Pharmazeutische zusammensetzungen zur behandlung von atemwegs- und entzündungskrankheiten
CA2814391C (en) 2010-10-20 2021-03-16 Valspar Sourcing, Inc. Water-based coating system with improved adhesion to a wide range of coated and uncoated substrates including muffler grade stainless steel
JP2013542243A (ja) 2010-11-15 2013-11-21 カトリーケ ウニヴェルシテイト ルーヴェン 新規な抗ウイルス性化合物
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
TWI527809B (zh) 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
WO2012130633A1 (en) 2011-03-25 2012-10-04 Boehringer Ingelheim International Gmbh Pyrazole compounds as crth2 antagonists
SI2709988T1 (sl) * 2011-05-16 2017-11-30 Actimis Pharmaceuticals, Inc. Postopek za pripravo (4,6-bis-dimetilamino-2- (4- (4- trifluorometilbenzoil-amino)benzil) primidin-5-il) ocetne kisline
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
EP2885307A1 (de) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituierte heterocyclyl-derivate und ihre verwendung als prostaglandin-d2-rezeptormodulatoren
WO2014079806A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
RU2270194C2 (ru) * 2000-05-22 2006-02-20 Лео Фарма А/С Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (de) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydrochinolin-Derivate als CRTH2 Antagonisten
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
UA99138C2 (ru) 2007-06-21 2012-07-25 Актимис Фармасьютикалз, Инк. Частичка антагониста crth2 (варианты)
WO2008156781A1 (en) 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Amine salts of a crth2 antagonist

Also Published As

Publication number Publication date
ZA200508722B (en) 2006-12-27
EP1471057A1 (de) 2004-10-27
AU2004233966B2 (en) 2010-11-11
CY1111295T1 (el) 2015-08-05
AU2004233966A1 (en) 2004-11-11
PE20050143A1 (es) 2005-04-01
DK1633726T3 (da) 2011-03-28
PL1633726T3 (pl) 2011-06-30
US20100322980A1 (en) 2010-12-23
GT200400079A (es) 2004-11-30
ES2257616T3 (es) 2006-08-01
US7812160B2 (en) 2010-10-12
EP1471057B1 (de) 2006-01-18
ATE316077T1 (de) 2006-02-15
CN101914065A (zh) 2010-12-15
CA2523439A1 (en) 2004-11-11
JP5161290B2 (ja) 2013-03-13
NO20055588D0 (no) 2005-11-25
PT1471057E (pt) 2006-05-31
CN1809539B (zh) 2012-05-09
CN1809539A (zh) 2006-07-26
EP1633726B1 (de) 2011-01-05
SI1633726T1 (sl) 2011-04-29
TW200505873A (en) 2005-02-16
ATE494279T1 (de) 2011-01-15
US20070129355A1 (en) 2007-06-07
JP4671955B2 (ja) 2011-04-20
JP2006524645A (ja) 2006-11-02
DK1471057T3 (da) 2006-05-15
KR101110491B1 (ko) 2012-01-31
RU2361865C2 (ru) 2009-07-20
HK1095320A1 (en) 2007-05-04
DE602004030907D1 (de) 2011-02-17
JP2011068657A (ja) 2011-04-07
EP1633726A1 (de) 2006-03-15
MXPA05011399A (es) 2006-05-31
HN2004000129A (es) 2009-05-14
US7960393B2 (en) 2011-06-14
RU2005136655A (ru) 2006-06-10
CA2523439C (en) 2012-06-19
WO2004096777A1 (en) 2004-11-11
NZ543693A (en) 2009-05-31
MY147984A (en) 2013-02-28
ES2358424T3 (es) 2011-05-10
AR043885A1 (es) 2005-08-17
BRPI0409733A (pt) 2006-05-09
TWI353980B (en) 2011-12-11
CL43596B (es) 2005-03-18
UY28286A1 (es) 2004-11-30
PT1633726E (pt) 2011-02-22
DOP2004000875A (es) 2004-10-31
NO20055588L (no) 2006-01-24
IL171566A (en) 2011-03-31
KR20060089622A (ko) 2006-08-09
DE60303238T2 (de) 2006-09-14

Similar Documents

Publication Publication Date Title
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE390925T1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE502004008604D1 (de) Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE448219T1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ACTIMIS PHARMACEUTICALS, INC., SAN DIEGO, CALI, US